SP-MHCI-0775-3

HHV 3 (VZV, strain Dumas) Tegument protein VP22 217-229, TGAVIRITVHEGL

US$507.00

In stock

Description

About HHV 3 (VZV, strain Dumas) Tegument protein VP22 217-229, TGAVIRITVHEGL

The Varicella-zoster virus (VZV) Human herpesvirus 3, strain Dumas Tegument protein VP22 Peptide (IEDB: 435759) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Tegument protein Peptide, H-TGAVIRITVHEGL-OH (Uniprot: P09272 aa: 217-229) from JPT is produced under strict quality control and quality management.

HHV 3 (VZV, strain Dumas) Tegument protein VP22 217-229, TGAVIRITVHEGL - Specifications

  • Peptide sequence: H-TGAVIRITVHEGL-OH
  • Amount: 10 mg (10 x 1 mg)
  • Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
  • Counterion: TFA
  • Delivery Format: Freeze-dried in glass vial
  • Application(s): T-cell Immunity
  • Condition(s)/Topic(s): Herpes zoster
  • Standard Delivery Time: approx. 3 weeks

JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!

Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for HHV 3 (VZV, strain Dumas) Tegument protein VP22 217-229, TGAVIRITVHEGL

References:
Read References with JPT’s Antigen Peptides
HHV 3 (VZV, strain Dumas) Tegument protein VP22 217-229, TGAVIRITVHEGL has been described in:
Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus., J Infect Dis, 2015 (PMID: 25784732)
Varicella-zoster virus proteome-wide T-cell screening demonstrates low prevalence of virus-specific CD8 T-cells in latently infected human trigeminal ganglia., J Neuroinflammation, 2023 (PMID: 37308917)

Documentation

Documentation for HHV 3 (VZV, strain Dumas) Tegument protein VP22 217-229, TGAVIRITVHEGL

Properties

Properties of HHV 3 (VZV, strain Dumas) Tegument protein VP22 217-229, TGAVIRITVHEGL

Properties Values
Application: T-cell immunity
Category: Antigen Peptides
Condition / Topic: Herpes zoster
Layout: Freeze-dried in glass vial
Organism: Varicella-zoster virus (VZV)
Protein Name: Tegument protein
Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
Quantification: No, Yes

Further Information to HHV 3 (VZV, strain Dumas) Tegument protein VP22 217-229, TGAVIRITVHEGL

Information Values
Sequence: H-TGAVIRITVHEGL-OH
Specifications: 13mer peptide as TFA salt
Loading...

Check our list of products, click and go.

Get a quote